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Abstract
Background: Diabetes is associated with premature death and a number of serious complications. The presence of
comorbid depression makes these outcomes more likely and results in increased healthcare costs. The aim of this
work was to assess the health economic outcomes associated with having both diabetes and depression, and
assess the cost-effectiveness of potential policy changes to improve the care pathway: improved opportunistic
screening for depression, collaborative care for depression treatment, and the combination of both.
Methods: A mathematical model of the care pathways experienced by people diagnosed with type-2 diabetes in
England was developed. Both an NHS perspective and wider social benefits were considered. Evidence was taken
from the published literature, identified via scoping and targeted searches.
Results: Compared with current practice, all three policies reduced both the time spent with depression and the
number of diabetes-related complications experienced. The policies were associated with an improvement in
quality of life, but with an increase in health care costs. In an incremental analysis, collaborative care dominated
improved opportunistic screening. The incremental cost-effectiveness ratio (ICER) for collaborative care compared
with current practice was £10,798 per QALY. Compared to collaborative care, the combined policy had an ICER of
£68,017 per QALY.
Conclusions: Policies targeted at identifying and treating depression early in patients with diabetes may lead to
reductions in diabetes related complications and depression, which in turn increase life expectancy and improve
health-related quality of life. Implementing collaborative care was cost-effective based on current national guidance
in England.
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Background
Diabetes is a chronic condition associated with prema-
ture death and a number of serious complications such
as amputation, blindness and heart disease [1, 2]. Self-
management plays an important role in the treatment of
diabetes, however the presence of comorbid depression
is associated with poorer self-management, leading to
reduced adherence to medication and poorer glycaemic
control [3]. The effects of comorbid depression on out-
comes for people with diabetes are marked; mortality is
increased by over a third, the prevalence of complica-
tions is increased, and healthcare costs are 4.5 times
higher [4–6].
Historically services of care in the English National
Healthcare System (NHS) have been based around sin-
gle-disease guidelines, leading to “siloing” of care [7, 8].
However, in recent years there has been growing interest
in exploring methods by which the care pathways for
people with comorbid physical and mental health prob-
lems may be integrated, and in assessing the impact that
any resulting changes have on both patient outcomes and
costs to the healthcare system [4]. There is evidence that
addressing comorbid depression amongst people with dia-
betes can lead to improved outcomes and quality of life
[4]. For example, one study showed that implementing a
12-month depression treatment program for people with
diabetes led to reduced outpatient resource use [9].
Potential enhancements to the care pathway for individ-
uals with diabetes and depression include implementing
collaborative care, and improving rates of opportunistic
screening. Collaborative care is an enhancement to how
depression treatment is usually delivered. It requires an
additional healthcare professional, whose job is to improve
collaboration between the individual receiving depression
treatment and those delivering the depression treatment
[10]. It is recommended in English National Institute
for Health and Care Excellence (NICE) clinical guide-
lines for individuals with depression and a long-term
chronic physical health problem [11], and has been
shown to be effective in both the United Kingdom
(UK) [12] and the United States [13]. However, it is
not yet routinely implemented within the UK. Oppor-
tunistic screening refers to screening for depression
amongst routine primary care appointments unrelated
to depression. One method by which rates of oppor-
tunistic screening may be improved is as part of a
policy to screen individuals with diabetes for depres-
sion during every primary care appointment.
This study aimed to assess the cost-effectiveness of three
potential service changes to the current pathways of care
for individuals with both diabetes and depression. These
service changes were: implementing collaborative care,
improving opportunistic screening, and combining collab-
orative care with improved opportunistic screening.
Methods
A mathematical model was developed to assess the cost-
effectiveness of potential changes (policies) to the current
care pathways (standard care) experienced by people diag-
nosed with type-2 diabetes (T2DM) currently managed
within primary care in England. Patients could have existing
depression, develop depression, or remain depression free.
A group of expert advisors assisted in the identification of
both relevant service changes and relevant evidence.
Model structure
The patient-level mathematical model used discrete-
event simulation, and consisted of two inter-linked
disease-specific models for diabetes and depression. A
simplified schematic of the model is presented in Fig. 1.
The diabetes sub-model, which included mortality, was a
modification of the United Kingdom Prospective Diabetes
Study Outcomes Model version 2 (UKPDS OMv2), which
has been described in detail elsewhere [14]. Briefly, this
used patient characteristics (demographics and clinical
measurements) to assess the progression of diabetes risk
factors over time, and the development of diabetes-related
complications. Diabetes-related complications included
were either microvascular (ischaemic heart disease [IHD],
blindness or renal failure) or macrovascular (heart failure,
myocardial infarction [MI], stroke, diabetes ulcer or ampu-
tation). Both the risk of developing a diabetes-related com-
plication and the probability of dying were taken from
published regression models from the UKPDS OMv2,
based on an individual with T2DM’s diabetes-related risk
factors for complications and history of other complica-
tions. Progression rates for diabetes-related risk factors for
complications included in the UKPDS OMv2 have not
been published and hence were assumed to be constant.
This is similar to the approach used in other diabetes
models [15].
The depression sub-model was based on an existing
model of depression care pathways, which was adapted to
include minor (sub-threshold) depression as a separate
health state [16]. This sub-model included the natural his-
tory of depression in the absence of treatment (in the form
of incidence, remission and recurrence), and the impact of
depression screening and treatment on this natural history.
The two disease-specific models were linked by model-
ling a bi-directional relationship between depression and
diabetes-related complications such that individuals with
T2DM and diabetes-related complications were more
likely to experience depression; whilst patients with de-
pression were more likely to develop diabetes-related
complications. Successful depression treatment had the
potential to decrease the time to remission. Conversely,
the development of a diabetes-related complication had
the potential to increase the hazard of depression inci-
dence or recurrence.
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Model inputs
Model parameters were informed by literature reviews,
as described elsewhere [1]. Where possible, evidence was
taken from studies that considered patient populations
with both diabetes and depression. Otherwise, data from
patients with depression alone or patients with diabetes
irrespective of depression status were used supplemented
by expert opinion. The evidence for depression progres-
sion, screening and case-finding used in the economic
model is summarised in Table 1, whilst the evidence for
depression treatment is summarised in Additional file
1. Evidence used to inform the progression of
diabetes risk factors and the development of diabetes
related complications were taken from the UKPDS
OMv2 [14].
Baseline characteristics were taken mainly from the
National Diabetes Audit [17] and the UKPDS OMv2
[14]. Neither of these contained evidence on the preva-
lence of depression amongst individuals with T2DM; evi-
dence for major depression was taken from a cross-
sectional English study [18]. Further details about the
baseline characteristics are provided in Additional file 1.
The rate of progression from minor to major depression
was based on the randomised-controlled trial of Bot et
al. [19]. Evidence about the incidence of major depres-
sion and relapse rates amongst individuals with diabetes
were taken from a Dutch cohort study [20] and a
randomised-controlled trial [21] respectively. In the ab-
sence of suitable evidence, the incidence of, prevalence
of, and relapse rates for minor depression were assumed
to be the same as those for major depression.
The average annual number of routine primary care ap-
pointments for individuals with T2DM but no depression
was taken to be 12.5, based on published evidence [22]. It
was assumed that individuals with both T2DM and de-
pression would be less likely to engage with healthcare
services and so have an average of eight primary care ap-
pointments per annum (excluding any appointments relat-
ing to their depression treatment). It was presumed that
under the current care pathways, individuals with T2DM
and a history of depression had a 20% probability of re-
ceiving an opportunistic screen during a primary care ap-
pointment, and a 5% probability for individuals with
T2DM and no history of depression. It was assumed that
the Whooley questionnaire was used for depression
screening, with sensitivity and specificity taken from an
existing meta-analysis [11]. The choice of the Whooley
questionnaire for depression screening was motivated by
national guidance in the UK Quality and Outcomes
Framework [23]. Advisors concurred with this approach,
although they noted that in practice the Whooley ques-
tions may be asked formally or informally. Patients with a
positive screen underwent depression case-finding in the
form of a structured interview, which was assumed to ei-
ther confirm cases of depression (amongst people with de-
pression) or correct cases of incorrectly identified
depression (amongst people without depression).
Evidence on the effectiveness of depression treat-
ment was taken from meta-analyses for both
pharmacotherapy [24] and low-intensity psychother-
apy [25]. Evidence for high-intensity psychotherapy
was taken from an existing economic evaluation
Fig. 1 Simplified model schematic
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[16], who considered depression amongst the general
population.
The bi-directional association between depression and
diabetes-related complications
Based on the available evidence [1] and discussions with
advisors, it was assumed that there was a bi-directional
association between depression and diabetes-related
complications, such that:
 Individuals with T2DM and depression had a higher
risk of developing diabetes-related complications
 Individuals with T2DM and diabetes-related
complications had a higher hazard of developing
depression.
This association was incorporated within the model
via a set of hazard ratios. Individuals with T2DM had an
annual probability of developing a diabetes-related com-
plication based on the UKPDS risk equations [14]. If an
individual with T2DM had depression this risk was ele-
vated in the model, based on the amount of time spent
with depression in the preceding year (for example, if an
individual spent half of the year with depression, then
the elevated risk due to having depression was halved).
Further, if an individual with T2DM and depression was
receiving depression treatment, and they ultimately
responded to it, it was assumed that their time spent
with depression did not contribute towards an elevated
risk. The hazard ratios for developing a diabetes-related
complication due to having depression were taken from
Lin et al. [26], for microvascular disease they were 1.31 for
minor depression and 1.36 for major depression, whilst
for macrovascular disease they were 1.00 for minor de-
pression and 1.25 for major depression (values greater
than one indicate an increased risk). If an individual with
T2DM had a diabetes-related complication, the hazard for
developing depression was increased. It was assumed that
the hazard of developing depression was the same if indi-
viduals had one or several complications. No studies were
identified which estimated the effect of having a diabetes
complication on developing depression, so a hazard ratio
of 1.5 was assumed for the effect of any diabetes complica-
tion on either minor or major depression. Further details
on how this association was modelled are provided in
Additional file 1. The robustness of model results to this
assumed value was tested in sensitivity analyses.
Health-related quality of life and costs
The baseline utility values (measured using the EQ-5D)
for patients with diabetes and the decrements in health-
related quality of life (HRQoL) associated with MI, IHD,
stroke, heart failure, amputation and blindness were
taken from the most recent analysis of the UKPDS [27].
Utility decrements associated with foot ulcers, severe
hypoglycaemia and renal failure were not reported in
this study and were sourced from the literature [28–30].
No studies were identified which reported on the impact
of depression on HRQoL for patients with diabetes.
These utility decrements were derived from a study
amongst patients with depression [31]. It was assumed
that the utility decrement due to depression was halved
for the duration of treatment if the individual ultimately
responded to treatment, reflecting the concept that
Table 1 Summary of parameters used for depression
progression, screening and case-finding
Parameters Value Source
Incidence of depression (per year) in patients with diabetes and no
history of depression
Minor 5.4% Assumption
Major 5.4% Nefs et al. [20]
Time to progression (years)
Minor to major depression 42% at
2 years
Bot et al. [19]
Time to relapse of depression for patients with a history of depression
(years)
Minor 1.359 Assumption
Major 1.359 Lutsman et al.
[21]
Time to spontaneous recovery (years)
Minor 0.354 NICE CG90 [24]
Major 0.877 Spijker et al.
(2002) [38]
Average annual number of GP
appointments (other than appointments
associated with depression treatment)
• cigDiabetes, no depression
• Diabetes with minor depression
• Diabetes with major depression
12.5
8
8
Bhattarai et al.
[22]
Assumption
Assumption
Probability that a GP appointment includes
a depression screen
• No history of depression
• History of depression
5%
20%
Assumption
Probability of attending annual diabetes
review
QOF 2012/13
[39] DM29
• No depression
• Minor depression
• Major depression
90.4%
RRa: 0.9
RRa: 0.65
Assumption
Assumption
Probability that the annual review
includes a depression screen
85.9% QOF 2012/13
[39] DEP1
Effectiveness of screening
• Sensitivity of Whooley questions
• Specificity of Whooley questions
• Sensitivity of structured interview
• Specificity of structured interview
95%
66%
100%
100%
NICE CG91 [11]
NICE CG91 [11]
Assumption
Assumption
aRR Relative risk. Values are relative to no depression, with values <1
indicating that patients are less likely to attend the annual diabetes review.
QOF Quality and outcomes framework
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HRQoL improved whilst on successful treatment. Esti-
mates of resource use and unit costs were taken from na-
tional sources and from the literature [16, 32]. An
overview of the costs and utilities is provided in Table 2,
with details about resource use for depression treatment
available in Additional file 1 (section B). In general, re-
source use and costs for depression treatment came from
the economic evaluation of Tosh et al. [16]. The costs of
treating diabetes and its complications were taken from
Clarke et a.l [32]. Remaining costs were primarily based
on national sources or assumptions where evidence was
lacking. Based on discussions with advisors, it was unclear
if implementing an opportunistic screen for depression
would lead to an increase in the costs of a GP appoint-
ment. For the base-case an additional cost of £2 was used;
two sensitivity analyses considered having no additional
cost, and an additional cost of £4. Further detail on how
the costs were derived is available elsewhere [1].
Policy changes modelled
The policy of implementing collaborative care was mod-
elled as an enhancement to the existing care pathway for
individuals with depression and diabetes. The additional
resource use associated with collaborative care was
based on resource use patterns described in NICE clin-
ical guideline 91 [11]. Implementing collaborative care
was assumed to decrease the probability of drop-out
(relative risk 1.33) and increase the probability of
responding to depression treatment (relative risk 1.79),
with evidence taken from a meta-analysis by Huang et al.
[33]. Further details on the implementation of collabora-
tive care are available in Additional file 1 (section C).
Under the policy of improved opportunistic screening,
it was assumed that every primary care appointment for
individuals with diabetes included an opportunistic
screen for depression (with costs as detailed in Table 2),
unless the individual had identified depression.
The combined policy included the costs and effects for
both collaborative care and improved opportunistic
screening, with no further changes.
Assessment of cost-effectiveness
Health economic outcomes were summarised using the
incremental cost effectiveness ratio (ICER), defined as
incremental costs divided by incremental quality ad-
justed life years (QALYs). The clinical outcomes consid-
ered were the number of diabetes-related complications
and the number of depressive episodes (identified and
unidentified) experienced by an individual with T2DM.
The analysis took the perspective of the NHS and social
services. Wider societal benefits were also explored
which considered the impact on productivity (days off
work due to ill-health) and informal care (days received
any unpaid care provided by family or friends). This
Table 2 Costs and utilities used in the economic model
Unit costs
GP appointment £37 PSSRU [40]
Annual review £397 NAO [41]
Opportunistic screening
for depression
£2 Assumption
Antidepressants (daily costs) £0.073 Tosh et al. [16]
IAPT per session £88 Tosh et al. [16]
Diabetes-related complications*
Diabetes — no complications £252 Clarke et al. [32]
CHF — year of event /
subsequent years
£3,559 /
£1,01
Clarke et al. [32]
IHD — year of event /
subsequent years
£3,139 / £790 Clarke et al. [32]
MI — year of event /
subsequent years
£6,522 / £744 Clarke et al. [32]
Stroke — year of event /
subsequent years
£3,793 / £399 Clarke et al. [32]
Blindness — year of event /
subsequent years
£1,397 / £450 Clarke et al. [32]
Ulcer — year of event /
subsequent years
£1,855 / £21 Ghatnekar et al.
[42]
Amputation — year of event /
subsequent years
£13,556 /
£481
Clarke et al. [32]
Renal failure — year of event /
subsequent years
£34,806 /
£34,806
NICE STA for
dapagliflozin [43]
Severe hypoglycaemia £390 NICE STA for
dapagliflozin [43]
Health state utilities Value References
Baseline 0.807 Alva et al. [27]
Decrements
MI (year before) −0.065 Alva et al. [27]
MI (prior history) 0.008 Alva et al. [27]
IHD −0.028 Alva et al. [27]
Stroke −0.165 Alva et al. [27]
Heart Failure −0.101 Alva et al. [27]
Amputation −0.172 Alva et al. [27]
Blindness 0.033 Alva et al. [27]
Renal failure −0.263 Klarenbach
et al. [29]
Foot ulcer −0.016 Sollie et al. [28]
Severe Hypoglycaemia −0.00186 Marrett et al. [30]
Minor depression 0 Kaltenthaler
et al. [31]
Major depression −0.3 Kaltenthaler
et al. [31]
Effect of being on depression
treatment on the decrement
for major depression; responders
only (multiplier)
x0.5 Assumption
*Uplifted to 2013 prices
GP General practitioner, MI myocardial infarction, IHD ischaemic heart disease
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was based on methodology developed to inform the
Department of Health’s proposed approach to Value
Based Pricing [34].
Costs were reported in 2013 British Pound Sterling. A
lifetime horizon was used. Both costs and QALYs were
discounted at a rate of 3 · 5 per cent per year [35]. All re-
sults were estimated by running 600,000 patients
through the mathematical model, and multiplying-up
the results to reflect those for a cohort of 2,000,000
adults diagnosed with T2DM in England [17].
Assessment of uncertainty
A Probabilistic sensitivity analysis was not performed
due to computational restrictions. Thirty univariate sen-
sitivity analyses were conducted by changing the values
of specified model inputs and assessing the impact on
the health economic results. These sensitivity analyses
included changes to the natural history of depression,
the bi-directional association between having a diabetes-
related complication and depression, the magnitude of
disutility due to having depression, and the costs of
screening and collaborative care. Further details are
available in Additional file 1.
Results
Number of diabetes-related complications and depressive
episodes
Predicted lifetime clinical outcomes experienced by the
cohort for current practice and each of the policy
changes are displayed in Table 3. Under current practice
the cohort would experience approximately 1.5 million
diabetes-related complications. All three policy changes
produced a reduction in both microvascular and macro-
vascular diabetes-related complications. The combined
policy (collaborative care and improved opportunistic
screening) avoided the greatest proportion of complica-
tions; about 1.5%, whilst the other two policies both
avoided about 1%.
It was predicted that the cohort would experience
about 15.5 million depressive episodes under current
clinical practice over their lifetime, of which just over
half (51%) would be identified. Implementing collabora-
tive care did not affect the proportion of identified de-
pression episodes, as this service change only affects
depression treatment. However, implementing improved
opportunistic screening, either on its own or in combin-
ation with collaborative care was estimated to increase
the proportion of identified cases to approximately 87%.
Health economic outcomes
Results of the cost-effectiveness analysis are provided in
Table 4. Of the three service changes considered, the
combined policy was estimated to have the largest im-
pact on both life years and QALYs compared with
current practice, with increases of 0.6 and 1.8% respect-
ively. These increases were driven by a reduction in the
number of diabetes related complications. The largest
reductions were observed for renal failure and amputa-
tion, which also have the largest impact on HRQoL.
However, this policy was also associated with the largest
Table 3 Lifetime incidence of diabetes-related complications and depression episodes
Results per 2,000,000 people Current practice (CP) Policy 1a Policy 2b Policy 3c Policy 1 — CP Policy 2 — CP Policy 3 — CP
Number of microvascular complications
Blindness 116,237 114,360 115,070 113,287 −1,877 −1,167 −2,950
Renal failure 68,633 66,840 66,890 66,150 −1,793 −1,743 −2,483
Diabetic ulcer 69,320 68,803 68,633 67,920 −517 −687 −1,400
Amputation 87,017 85,303 85,450 84,560 −1,713 −1,567 −2,457
Total 341,207 335,306 336,043 331,917 −5,900 −5,164 −9,290
Number of macrovascular complications
IHD 277,880 275,627 276,923 274,883 −2,253 −957 −2,997
MI 377,417 374,227 374,190 373,437 −3,190 −3,227 −3,980
Stroke 274,880 273,010 272,980 271,650 −1,870 −1,900 −3,230
CHF 221,130 219,640 219,250 218,587 −1,490 −1,880 −2,543
Total 1,151,307 1,142,504 1,143,343 1,138,557 −8,803 −7,964 −12,750
Number depression episodes (1,000)
Total number 15,517 15,598 15,563 15,605 80 46 88
Identified 7,937 7,983 13,547 13,588 46 5,610 5,650
Unidentified 7,580 7,615 2,016 2,018 35 −5,564 −5,562
CP Current practice, IHD Ischaemic heart disease, MI Myocardial infarction, CHF Congestive heart failure. aPolicy 1 = collaborative care; bPolicy 2 = opportunistic
screening; cPolicy 3 = both collaborative care and opportunistic screening
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increases in lifetime healthcare costs, with an increase
compared to current practice of £9.6 billion (23.2%)
from £41.6 billion. Increases for the other policies were:
collaborative care £6.7 billion (16.2%) and improved op-
portunistic screening £1.6 billion (3.9%). The main
drivers for increased costs were an increase in the costs
of treating depression, and an increase in the costs of
the diagnostic interview (for the two policies that in-
cluded changes in opportunistic screening).
Wider societal benefits
All three policy changes led to a reduction in both the
number of informal care days received and the number
of days off paid employment due to ill health. Reduc-
tions were largest for the combined policy and smallest
for the policy of improved opportunistic screening on its
own. The estimated QALY loss due to depression was
1,746 for current practice. Each of the policies was asso-
ciated with a reduction in lost QALYs, with the largest
reduction for the combined policy (1,631; 6.6% of the
value for current practice).
Incremental cost effectiveness ratio
Under an incremental analysis, improved opportunistic
screening was dominated by collaborative care being
both more expensive and less effective. The ICER for
collaborative care compared to current practice was esti-
mated at £10,798 per QALY gained, whilst the ICER for
the combined policy compared to collaborative care
alone was estimated at £68,017 per QALY. Based on
these results, the use of collaborative care would be rec-
ommended if using the threshold for cost-effectiveness
of £13,000 per QALY, which has been estimated to be
the current threshold in the NHS [36].
The results of one-way sensitivity analyses indicated
that the cost-effectiveness results were most sensitive to
the estimated time until relapse, and the hazard ratio for
depression affecting diabetes-related complications. Re-
sults were robust to the majority of the other parameters
varied. Full results of the sensitivity analyses are available
in Additional file 1.
The results presented in Table 4 demonstrate that the
key drivers for differences in cost between the policies
were related to depression diagnosis, screening and
treatment. In contrast, differences in QALYs gained were
due to improvements in both diabetes and depression
outcomes. If only depression outcomes had been consid-
ered, then the ICERs compared with usual practice
(£17,000, £91,000 and £50,000 for policies 1, 2 and 3 re-
spectively) would have been higher than when consider-
ing both diabetes and depression. Hence, if only
outcomes relating to depression were considered then
the cost-effectiveness of each of the policies would have
been under-estimated.
Discussion
This study examined the potential cost-effectiveness of
three policies for individuals with T2DM and depression
in England. These policies represented potential service
changes: improvements in opportunistic screening for
Table 4 Cost-effectiveness results
Discounted results (Results per 2,000,000 people) Current
practice (CP)
Policy 1a Policy 2b Policy 3c Policy 1 — CP Policy 2 — CP Policy 3 — CP
Life years (1,000) 19,515 19,580 19,564 19,601 65 49 86
QALYs (1,000) 12,006 12,103 12,082 12,188 97 76 182
Informal care (1,000) 4,975 4,947 4,953 4,898 −27 −22 −77
Days off sick (100) 1,733 1,705 1,711 1,673 −27 −21 −60
QALY loss due to depression (1,000) 1,746 1,695 1,702 1,631 −51 −44 −115
Costs (2013, £1,000,000) 29,626 30,676 34.475 36,431 1,050 4,849 6,805
Costs (2013 UK £1,000,000) Undiscounted
Complications management 9,833 9,644 9,459 9,428 −190 −374 −405
Annual review 9,134 9,222 9,200 9,294 88 66 161
Primary care management 11,169 11,337 11,281 11,470 167 112 300
Ongoing diabetes management
(excluding above)
6,833 6,865 6,856 6,875 31 23 42
Diagnostic interview 1,271 1,320 5,588 5,840 50 4,317 4,569
Opportunistic screening 107 112 547 574 5 440 467
Depression treatment 3,215 4,666 5,349 7,728 1,451 2,134 4,513
Total cost 41,562 43,165 48,281 51,209 1,603 6,719 9,647
CP Current practice, IHD Ischaemic heart disease, MI Myocardial infarction, CHF Congestive heart failure. aPolicy 1 = Collaborative care; bPolicy 2 = Opportunistic
screening; cPolicy 3 = both collaborative care and opportunistic screening
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depression; collaborative care; or a combination of the
two. Under current practice the modelled cohort experi-
enced 1.5 million diabetes-related complications, with a
cost to the healthcare system of £41.6 billion. All three
policies reduced both the number of unidentified de-
pressive episodes, and the number of diabetes-related
complications. All three policies were associated with an
improvement in HRQoL, but also with an increase in
health care costs. Assuming a willingness to pay thresh-
old of £13,000 per QALY, only collaborative care was
cost-effective.
A strength of this study was that it considered the en-
tire depression pathway of care as experienced by the
majority of individuals with T2DM and comorbid de-
pression. This allowed for a comparison of different
types of policy change within a single model, and so re-
duced variation by using a consistent modelling frame-
work for generating cost-effectiveness evidence. The
mathematical model was also based on two previously
published and validated models, which lends validity to
the results presented.
As is normal in healthcare modelling, the mathemat-
ical model represents a simplification of reality and the
results presented here need to be interpreted in relation
to the assumptions used and evidence available. The
main limitation with this study was the lack of relevant
and robust evidence for many of the parameters. Much
of the evidence about the natural history of depression
amongst individuals with T2DM came from studies con-
ducted in the Netherlands and the relevance of this evi-
dence to a UK setting is unclear. Evidence for other
parameters was obtained from studies of individuals with
depression amongst the general population which may
not generalize to individuals with depression and T2DM.
The results of sensitivity analyses showed that the mod-
elled association between having depression and devel-
oping diabetes-related complications was an important
determinant of cost-effectiveness. The evidence for this
association was limited as it was derived from a single
non-randomised study{Lin, 2010 5299 /id}. A further
limitation was the lack of probabilistic sensitivity analysis
to evaluate the uncertainty in the results. Had such an
analysis been undertaken, it would have been possible to
perform value of information analyses, to quantify how
uncertainty in each of the model inputs contribute to
uncertainty in the cost-effectiveness results, and how
much it would be worth spending on further research to
reduce this uncertainty [37]. However, twenty nine uni-
variate sensitivity analyses were conducted on key model
parameters. The results of these sensitivity analyses sug-
gested that the modelled results remained relatively ro-
bust to changes in a number of assumptions.
An important aspect of this study was the modelled
bi-directional association between having a diabetes-
related complication and depression. This association
was modelled via hazard ratios. A more realistic repre-
sentation may have been to explicitly model the causes
for the bi-directional association; for example having de-
pression may lead to poorer self-management which may
affect risk factors for diabetes-related complications such
as control of HbA1c or smoking status. This was not per-
formed for this study due to a lack of robust evidence.
The risk of diabetes related complications is affected by
long-term changes in the control of HbA1c, and it is un-
certain if a short-term benefit due to reducing time with
depression will have a substantial effect on this risk of
complications. Because of this, an explicit causal model of
the bi-directional association may have led to more reli-
able estimates of the impact of policies aimed at improv-
ing depression identification and the treatment of
depression. In addition, there remains considerable uncer-
tainty concerning the association between having a
diabetes-related complication and developing depression
as no studies were identified which quantified the magni-
tude of this association.
If longitudinal data on the bi-directional association
were available, this would help to establish the causal re-
lationships between diabetes-related complications and
depression.
Additional research is required to improve the evi-
dence base and hence increase confidence in the results
presented. There is a paucity of evidence on the natural
history of depression in patients with diabetes and how
it is affected by developing a diabetes-related complica-
tion. Evidence about the HRQoL of individuals with dia-
betes and depression is also required, as is stronger
evidence about the bi-directional association between
having a diabetes-related complication and depression.
To the authors’ knowledge, this is the first economic
evaluation of potential changes to the care pathway for
individuals with T2DM and depression. The majority of
existing models assess the policy implications for single
conditions in isolation [14, 16]. An economic evaluation
performed to support NICE clinical guidance modelled
the cost-effectiveness of collaborative care amongst
people with depression and a chronic physical health
problem [11]. However, in this analysis collaborative
care only had an impact on depression outcomes; the
impact on any comorbid diseases was not modelled.
The results from the current analyses suggest that the
health-economic benefits from any policy change ac-
crue via changes to both conditions (for example im-
provements in HRQoL due to a reduction in both
diabetes-related complications and the number of un-
identified episodes of depression). Hence the health-
economic benefits suggested by other models may be
under-estimated if the impact of multi-morbidity is
not taken into account.
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Conclusions
Using the evidence currently available, the results of this
research suggest that policies targeted at identifying and
treating depression early in patients with diabetes may
lead to a reduction in diabetes related complications and
depression, which in turn increase life expectancy and
improve HRQoL. The policy change of collaborative care
was estimated to be cost-effective under the current
NHS threshold.
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